Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 122,141 |
|
|||||
| News | - | ||||||
| Day High | 1.34 | Low High |
|||||
| Day Low | 1.28 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Ikena Oncology Inc | IKNA | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.01 | -0.76% | 1.30 | 16:02:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.30 | 1.28 | 1.34 | 1.30 | 1.31 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,125 | 122,141 | $ 1.29 | $ 158,012 | - | 1.02 - 7.64 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 18:17:03 | 1 | $ 1.28 | USD |
Ikena Oncology Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 62.25M | 48.26M | - | 9.16M | -68.17M | -1.41 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Ikena Oncology News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical IKNA Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.25 | 1.42 | 1.25 | 1.32 | 225,896 | 0.05 | 4.00% |
| 1 Month | 1.42 | 1.46 | 1.22 | 1.32 | 234,337 | -0.12 | -8.45% |
| 3 Months | 1.35 | 1.65 | 1.22 | 1.43 | 408,389 | -0.05 | -3.70% |
| 6 Months | 4.10 | 4.625 | 1.02 | 1.52 | 323,739 | -2.80 | -68.29% |
| 1 Year | 4.87 | 7.64 | 1.02 | 2.50 | 214,034 | -3.57 | -73.31% |
| 3 Years | 21.03 | 26.4899 | 1.02 | 5.82 | 160,396 | -19.73 | -93.82% |
| 5 Years | 22.40 | 37.61 | 1.02 | 6.76 | 166,169 | -21.10 | -94.20% |
Ikena Oncology Description
| Ikena Oncology Inc is a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. Its lead targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, transcription factor in the Hippo signaling pathway. The Hippo pathway is genetically altered in approximately 10% of human cancers and is widely accepted as a prevalent driver of cancer pathogenesis and a mediator of poor outcomes for patients. |
